Tianhong Li
Department of Oncology
Montefiore Medical Center & the Albert Einstein College of Medicine
Bronx
NY, United States
Name/email consistency: high
- Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Li, T., Ho, L., Piperdi, B., Elrafei, T., Camacho, F.J., Rigas, J.R., Perez-Soler, R., Gucalp, R. Lung. Cancer (2010)
- Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Li, T., Christos, P.J., Sparano, J.A., Hershman, D.L., Hoschander, S., O'Brien, K., Wright, J.J., Vahdat, L.T. Ann. Oncol. (2009)
- Skin toxicities associated with epidermal growth factor receptor inhibitors. Li, T., Perez-Soler, R. Target. Oncol (2009)
- Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. Li, T., Ling, Y.H., Perez-Soler, R. J. Thorac. Oncol (2008)
- Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Li, T., Yang, W., Li, M., Byun, D.S., Tong, C., Nasser, S., Zhuang, M., Arango, D., Mariadason, J.M., Augenlicht, L.H. Mol. Nutr. Food. Res (2008)
- Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Li, T., Ling, Y.H., Goldman, I.D., Perez-Soler, R. Clin. Cancer Res. (2007)